InhaleRx Limited (IRX.AX)
AUD 0.03
(38.89%)
AUD 0.03
(38.89%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.38 Million AUD | 27.92% |
| 2022 | -1.92 Million AUD | -70.85% |
| 2021 | -1.12 Million AUD | -10.25% |
| 2020 | -1.02 Million AUD | 37.75% |
| 2019 | -1.64 Million AUD | 17.45% |
| 2018 | -1.98 Million AUD | 2.91% |
| 2017 | -2.04 Million AUD | -486.1% |
| 2016 | -349.21 Thousand AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -318.25 Thousand AUD | 59.25% |
| 2024 Q2 | -318.25 Thousand AUD | 0.0% |
| 2023 Q2 | -1.84 Million AUD | -162.24% |
| 2023 Q1 | -704.12 Thousand AUD | 31.17% |
| 2023 FY | -2.62 Million AUD | -36.59% |
| 2023 Q4 | -781.02 Thousand AUD | -10171.17% |
| 2023 Q3 | -7604.00 AUD | 99.59% |
| 2022 FY | -1.92 Million AUD | -70.85% |
| 2022 Q4 | -1.02 Million AUD | -100.0% |
| 2022 Q2 | -931.08 Thousand AUD | -100.0% |
| 2022 Q1 | -465.54 Thousand AUD | 16.25% |
| 2022 Q3 | -511.5 Thousand AUD | 45.06% |
| 2021 FY | -1.12 Million AUD | -10.25% |
| 2021 Q4 | -555.84 Thousand AUD | -100.0% |
| 2021 Q1 | -277.81 Thousand AUD | 62.43% |
| 2021 Q2 | -555.63 Thousand AUD | -100.0% |
| 2021 Q3 | -277.91 Thousand AUD | 49.98% |
| 2020 FY | -1.02 Million AUD | 37.75% |
| 2020 Q4 | -739.42 Thousand AUD | -100.0% |
| 2020 Q1 | -233.07 Thousand AUD | 73.8% |
| 2020 Q2 | -466.15 Thousand AUD | -100.0% |
| 2020 Q3 | -369.71 Thousand AUD | 20.69% |
| 2019 Q2 | -1.05 Million AUD | -98.46% |
| 2019 Q1 | -529.97 Thousand AUD | -11.1% |
| 2019 Q3 | -420.46 Thousand AUD | 60.02% |
| 2019 FY | -1.64 Million AUD | 17.45% |
| 2019 Q4 | -889.62 Thousand AUD | -111.58% |
| 2018 Q1 | -486.91 Thousand AUD | 29.93% |
| 2018 FY | -1.98 Million AUD | 2.91% |
| 2018 Q4 | -477.01 Thousand AUD | 0.0% |
| 2018 Q3 | -477.01 Thousand AUD | 2.03% |
| 2018 Q2 | -486.91 Thousand AUD | 0.0% |
| 2017 Q2 | -679.94 Thousand AUD | 0.0% |
| 2017 Q4 | -694.93 Thousand AUD | 0.0% |
| 2017 FY | -2.04 Million AUD | -486.1% |
| 2017 Q1 | -679.94 Thousand AUD | 0.0% |
| 2017 Q3 | -694.93 Thousand AUD | -2.2% |
| 2016 FY | -349.21 Thousand AUD | 0.0% |
| 2016 Q2 | -31.16 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| 4DMedical Limited | -27.96 Million AUD | 95.042% |
| Adherium Limited | -11.98 Million AUD | 88.432% |
| Aroa Biosurgery Limited | -9.78 Million AUD | 85.834% |
| Atomo Diagnostics Limited | -4.36 Million AUD | 68.211% |
| Anteris Technologies Ltd | -66.63 Million AUD | 97.919% |
| Control Bionics Limited | -5.92 Million AUD | 76.616% |
| CardieX Limited | -4.63 Million AUD | 70.078% |
| Compumedics Limited | -269 Thousand AUD | -415.423% |
| Cochlear Limited | 521.5 Million AUD | 100.266% |
| CleanSpace Holdings Limited | -4.81 Million AUD | 71.199% |
| Cyclopharm Limited | -9.22 Million AUD | 84.97% |
| EMVision Medical Devices Ltd | -1.61 Million AUD | 14.118% |
| Nova Eye Medical Limited | -3.79 Million AUD | 63.485% |
| HeraMED Limited | -6.42 Million AUD | 78.43% |
| Imricor Medical Systems, Inc. | -17.57 Million AUD | 92.111% |
| ImpediMed Limited | -19.03 Million AUD | 92.717% |
| LBT Innovations Limited | -4.74 Million AUD | 70.749% |
| Micro-X Limited | -13.02 Million AUD | 89.357% |
| Neurotech International Limited | -5.58 Million AUD | 75.174% |
| OncoSil Medical Limited | -11.98 Million AUD | 88.431% |
| PolyNovo Limited | 1.16 Million AUD | 219.216% |
| Respiri Limited | -7 Million AUD | 80.194% |
| SomnoMed Limited | -3.84 Million AUD | 63.906% |
| Universal Biosensors, Inc. | -16.68 Million AUD | 91.688% |
| Uscom Limited | -2.4 Million AUD | 42.334% |
| Visioneering Technologies, Inc. | -5.85 Million AUD | 76.316% |